您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Rufinamide-15N-d2
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Rufinamide-15N-d2
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Rufinamide-15N-d2图片
包装:1mg
规格:98%
市场价:3185元
分子量:241.2

产品介绍
An internal standard for the quantification of rufinamide
货号:ajcx24796
CAS:1795037-48-7
分子式:C10H6D2F2N3[15N]O
分子量:241.2
溶解度:Acetonitrile: slightly soluble,DMSO: slightly soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Rufinamide-15N-d2is intended for use as an internal standard for the quantification of rufinamide by GC- or LC-MS. Rufinamide is an anticonvulsant.1It inhibits the activation of voltage-gated sodium channel 1.1 (Nav1.1) when used at a concentration of 100 µM.2Rufinamide inhibits Nav1.1, but not Nav1.2, Nav1.3, and Nav1.6, opening and increases the action potential threshold in primary rat hippocampal neurons. It is an inhibitor of carbonic anhydrase VA (CAVA; Ki= 343.8 nM) that is selective for CAVA over CAI and CAII (Kis = >10,000 nM for both).3Rufinamide (100 µM) prolongs the preictal phase and reduces seizure-like event frequency in anin vitromodel of epileptiform activity in rat hippocampal slices.4It inhibits seizures induced by pentylenetetrazole in a mouse model of epilepsy (ED50= 54 mg/kg, i.p.) and reduces kainic acid-induced neuronal cell death in the mouse hippocampal CA3 region when used at doses of 25, 50, and 100 mg/kg.5,6Formulations containing rufinamide have been used in the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS).


1.Wheless, J.W., and Vazquez, B.Rufinamide: A novel broad-spectrum antiepileptic drugEpilepsy Curr.10(1)1-6(2010) 2.Gilchrist, J.J., Dutton, S., Diaz-Bustamante, M., et al.Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodentsACS Chem. Biol.9(5)1204-1212(2014) 3.Costa, G., Carta, F., Ambrosio, F.A., et al.A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitorsEur. J. Med. Chem.181111565(2019) 4.GÁll, Z., OrbÁn-Kis, K., and SzilÁgyi, T.Differential effects of sodium channel blockers on in vitro induced epileptiform activitiesArch. Pharm. Res.40(1)112-121(2017) 5.White, H.S., Franklin, M.R., Kupferberg, H.J., et al.The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure modelsEpilepsia49(7)1213-1220(2008) 6.Park, J.-A., and Lee, C.-H.Effect of Rufinamide on the kainic acid-induced excitotoxic neuronal death in the mouse hippocampusArch. Pharm. Res.41(7)776-783(2018)